News · 26 weeks900%
2026-03-012026-08-23
Mix3090d
- Insider14(47%)
- Other9(30%)
- SEC Filings6(20%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Executive Officer Modig Berndt sold $79,686 worth of shares (2,292 units at $34.77) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 130,625 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.SCHEDULE 13G/A - Pharvaris N.V. (0001830487) (Subject)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERPresident Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.35% to 65,179 units (SEC Form 4) to satisfy tax liability4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 6-K filed by Pharvaris N.V.6-K - Pharvaris N.V. (0001830487) (Filer)
- PRPharvaris Reports Second Quarter 2026 Financial Results and Provides Business UpdateTopline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksStrong financial position with cash and cash equivalents of €318 million as of June 30, 2026 ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykin
- PRAssessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in ImmunologyPeople with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-beingStudy results informed the design and endpoint selection of the ongoing Phase 3 CREAATE study ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experien
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.SCHEDULE 13G/A - Pharvaris N.V. (0001830487) (Subject)
- PRPublication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated AngioedemaProvides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a compr
- INSIDERChief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- ANALYSTWells Fargo initiated coverage on Pharvaris N.V. with a new price targetWells Fargo initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $55.00
- INSIDERChief Medical Officer Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.34% to 65,405 units (SEC Form 4) (tax withholding)4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- PRPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema AttacksIf approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profilePDUFA action date set for April 23, 2027 ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announce
- INSIDERDirector Schikan Johannes Gerardus Christiaan Petrus sold $1,331,496 worth of shares (37,600 units at $35.41) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 315,167 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Early Development Lesage Anne exercised 38,472 shares at a strike of $6.85 and sold $2,695,452 worth of shares (76,172 units at $35.39) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 58,750 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Early Development Lesage Anne exercised 2,300 shares at a strike of $4.73 and sold $161,560 worth of shares (4,600 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERDirector Schikan Johannes Gerardus Christiaan Petrus sold $84,250 worth of shares (2,400 units at $35.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 352,767 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Medical Officer Lu Peng exercised 29,700 shares at a strike of $2.59 and sold $1,018,832 worth of shares (29,700 units at $34.30) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 6-K filed by Pharvaris N.V.6-K - Pharvaris N.V. (0001830487) (Filer)
- INSIDERChief Medical Officer Lu Peng exercised 300 shares at a strike of $2.59 and sold $10,200 worth of shares (300 units at $34.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Executive Officer Modig Berndt sold $71,173 worth of shares (2,291 units at $31.07) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 135,209 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Medical Officer Lu Peng covered exercise/tax liability with 117 shares, decreasing direct ownership by 0.18% to 65,631 units (SEC Form 4) (withholding obligation)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Medical Officer Lu Peng covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.17% to 65,748 units (SEC Form 4) to cover withholding tax4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
PHVS FAQ
7 questionsWhat does Pharvaris N.V. do?
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and...Where does PHVS stock trade?
Pharvaris N.V. (PHVS) is listed on NASDAQ.What sector and industry is PHVS in?
Pharvaris N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pharvaris N.V. go public?
Pharvaris N.V. (PHVS) completed its IPO in 2021.What are analysts saying about PHVS?
Pharvaris N.V. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight on 2026-07-15. Recent price targets range from $2700.00 to $4200.00.What companies are similar to PHVS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PHVS side-by-side with any of them on Quantisnow.How can I track PHVS on Quantisnow?
Quantisnow aggregates Pharvaris N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHVS to receive live email and push alerts on every new disclosure.